Virta Health, a company on a mission to reverse Type 2 diabetes, today announced that it has raised $93 million in Series C funding to combat the growing prevalence of Type 2 diabetes.
The company says the funding will allow it to invest in growth to meet the demand for Type 2 diabetes reversal from employers, health plans and government. It will also invest in further prospective research to expand its treatment to other diseases.
“This latest funding is validation for the consistency and durability of our health and economic outcomes in both clinical trial and commercial patients,” said Sami Inkinen, Virta Health’s co-founder and CEO in a press release. “We can now invest more in growth to help millions of people living with Type 2 diabetes, while also investing in product and research to address other diseases.”
Virta’s treatment is based on nutritional ketosis. The company stands by principles that if people change their food choices to eat fewer carbohydrates and more healthy fats, it will help people with diabetes to control their blood glucose levels and recover their metabolic health.
How Does It Work?
The Virta Support System. Image Courtesy: Virta Health.
The company uses a specialized technology-enabled continuous remote care model with individualized guidance for achieving nutritional ketosis.
Each patient has a remote care team made up of a health coach and a medical provider that continuously customize their care, track patient biomarkers and provide regular remote appointments.
Patients also receive behavioral support and encouragement from their coaches and an online community of their peers. As well as access to a host of recipes, videos, and guides.
“We hypothesized that this comprehensive care model would improve health for patients with Type 2 diabetes, allowing them to actually reverse hyperglycemia and insulin resistance while removing medications,” the company website indicates.
To assess the safety and efficacy of the treatment, Verta conducted a clinical trial, enrolling 262 adult volunteers with Type 2 diabetes who chose to receive the Virta Treatment.
For comparison, 87 adult volunteers who chose to receive the usual care for Type 2 diabetes were also enrolled.
At 1 year, participants who received the Virta Treatment saw clinically-significant benefits in their health outcomes, such as decreased HbA1c and weight, all while discontinuing 63% of diabetes-specific medications.
The company has extended the clinical trial out to 5 years and is closely following the clinical trial participants to learn more.
Virta Health is a licensed medical provider in all 50 states. Services start at $249/month.
To learn more about Virta’s novel continuous remote care platform, visit www.virtahealth.com.
- Virta Health. (Jan. 10, 2019). Virta Health Raises $93M to Combat the $400B Type 2 Diabetes Epidemic and Expand Diabetes Reversal to Millions. GlobeNewswire. Retrieved Jan. 10, 2019 from https://www.globenewswire.com/news-release/2020/01/10/1968937/0/en/Virta-Health-Raises-93M-to-Combat-the-400B-Type-2-Diabetes-Epidemic-and-Expand-Diabetes-Reversal-to-Millions.html